In intensified bioprocessing, the engineered CHO host supports higher titers and long culture duration in continuous perfusion.

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

WUHAN, HUBEI PROVINCE, CHINA, February 15, 2026 /EINPresswire.com/ — In the complex landscape of life science research, selecting the right cellular model is a ...

Researchers in the College of Agriculture, Health and Natural Resources have developed a novel line of bovine embryonic stem cells, which have significant potential for a variety of new innovations, ...

Host cell proteins (HCPs) are major process‐related impurities in biopharmaceutical manufacturing, imposing metabolic burden on production hosts and complicating downstream purification, thereby ...

Monoclonal antibody (mAb) production in CHO cells depends, among other factors, on balanced co-expression of the heavy (HC) and light (LC) chains. Imbalances between HC and LC can reduce titer, ...

Cell line creation is a major success factor in biologics manufacturing. It establishes the basis for product yield, quality, and long-term process stability. However, despite significant ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...

WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched TrueSite TI, a targeted integration (TI)-based CHO cell line platform designed to reshape ...